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ABSTRACT 
 
Background: Renewed interest in induction chemotherapy for treatment of locally advanced 
nasopharyngeal carcinoma has been made recently. Multiple phase III trials were going aiming to 
define the best candidate, and the best regimen for induction chemotherapy. We conducted this 
phase II study to evaluate the efficacy and safety of induction chemotherapeutic (TPF) regimen 
before CCRT with cisplatin weekly in locally advanced non metastatic NPC.  
Methods: 36 patients diagnosed with stage III, IVA & IVB, poorly differentiated or undifferentiated 
carcinoma in the period between August 2014 and August 2016 were included in the study, all of 
them received induction chemotherapy with TPF regimen followed by cisplatin (40 mg/m2) weekly 
concurrent with RT. Radiotherapy was given by 3D conformal modality where, high-risk GTVP, 
GTVLN & CTV was given a dose of 60 Gray / 30 fractions followed by 10-14 gray/5-7 fractions to 
GTVP and 6-10 Gray /3-5 fractions to GTVLN.  
Results: The objective response rate was 86% (CR 12%) in the primary tumor and, 100%                  
(CR 62%) in the cervical LN after induction chemotherapy and the corresponding rate was 100% 
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(CR 91%), 45-60 days after the completion of RT. No local recurrence or distant metastasis was 
seen during the follow-up period. The two-year DFS was 85% and the estimated two-year OS was 
95%. The rate of grade 3 /4 neutropenic fever was encountered in 6% of cases during induction 
chemotherapy. Grade 3/4 mucositis was seen in 9 % of patients while no grade 3 or 4 skin 
desquamation or xerostomia were seen. There was no treatment-related death. Field in field 
technique gave the best coverage of the PTV without exceeding the tolerance dose of other OAR. 
Conclusion: The TPF regimen was well tolerated and had a manageable toxicity profile. 3DCRT 
can be tailored to reach the target of Intensity modulation modalities.  
 
 
Keywords: Nasopharyngeal carcinoma; conformal radiotherapy; induction chemotherapy; TPF. 
 
1. INTRODUCTION 
 
Worldwide, there are about 85,000 incident 
cases and 55,000 deaths annually from 
nasopharyngeal carcinoma but with a high 
variation in the racial and geographical 
distribution with the highest prevalence in 
Southeast Asia and North Africa [1]. Owing to its 
silent, deeply seated site and vague, non-specific 
symptoms, its early detection is challenging as 
about 60–70% of cases present with locally 
advanced disease at diagnosis [2]. Concurrent 
chemo radiation is the standard treatment 
strategy for NPC in locally advanced stages              
[3-8]. However, the results of CCRT are 
suboptimal as over 20% of patients still 
experience distant metastasis after CCRT, 
necessitating exploration of other intensive 
treatment modalities for NPC as neoadjuvant 
chemotherapy, for improving the patients’ 
survival rates [9]. Multiple phase II trials have 
described better patient tolerance and treatment 
tolerability as regard induction chemotherapy 
versus adjuvant chemotherapy as well as a high 
locoregional response by reducing the tumor 
burden and killing occult micro-metastases. 
Multiple chemotherapeutic regimens as 
(bleomycin, gemcitabine, carboplatin, and 
taxanes) were investigated as a neoadjuvant line 
in locally advanced nasopharyngeal carcinoma 
[10-11]. The Controversy was still around the rule 
of NACT in locally advanced NPC as regards its 
impact on the overall survival in comparison with 
CCRT, who is the best candidate and what is   
the optimal regimen. These controversial                     
issues, makes the NCCN panel recommend 
NACT as category III after being class I.                  
These controversial issues answered by             
these phase III and meta-analytic studies 
(NCT01245959, NCT00828386, NCT01536223 
and NCT00201396) [12-17]. Intensity-modulated 
radiation therapy (IMRT) is the standard RT 
modality for treatment of head and neck cancer 
especially the NPC [18-19] but certain issues are 
related to IMRT, the most important are that they 
cannot be used universally due to unavailability 
of adequate equipment, organization or patient 
status. We initiated this study to evaluate the 
efficacy and tolerability of the TPF regimen 
followed by CCRT with 3D conformal RT 
modality in locally advanced NPC. We reported 
the two-year OS and the two-year DFS, and we 
have evaluated multiple fields arrangement of 
non-intensity modulation trying to achieve better 
coverage of the target and not exceeding the 
tolerance dose of the OAR.   
 
2. PATIENTS AND METHODS 
 
2.1 Eligibility Criteria Included 
  
Patients with stage III, IVA & IVB NPC, age 
between 18 and 70 years, ECOG PS of ≤ 2 and 
adequate organ function. Exclusion criteria 
included distant metastasis, abnormal body 
function or ECOG 3-4, history of surgery at the 
tumor site or neck except for diagnostic biopsy. 
Other exclusion criteria included a history of RT 
to the H&N region or history of any malignancy, 
second malignancy at the time of presentation, 
current pregnancy or joining another clinical trial 
at the time of our study. We took a written 
consent from all patients, and the ethical 
committee OF Mansoura University approved our 
trial. 
 
2.2 Treatment Regimens 
 
2.2.1 Pretreatment evaluation  
 
Pretreatment staging including clinical 
examination, radiological investigation (CT or 
MRI PNS & neck, chest CT), Bone scintigraphy 
and the abdominal US. Full ENT examination 
including endoscopy & biopsy and examination 
under anesthesia if needed and complete dental 
checkup and assurance about good oral hygiene. 
 
2.3 Treatment Details  
 
2.3.1 Chemotherapy 
 
All patients were planned to receive induction 
chemotherapy three cycles of TPF (docetaxel 75 
  
 
 
Abdulmohsen et al.; JCTI, 5(3): 1-11, 2017; Article no.JCTI.33794 
 
 
 
3 
 
mg/m2 D1 3 h infusion, cisplatin 75 mg/m2 D1 2 
hour infusion and 5 FU 1 g/m2 continuous IV 
infusion D1-D4). The cycle to be repeated every 
three weeks to be followed by cisplatin             
(40 mg/m2) weekly concurrent with RT. Growth 
Colony Stimulating Factor (GCSF) given when 
needed. Concurrent CRT with cisplatin 40 mg/m2 
weekly over one-hour infusion started 2-3 weeks 
after finishing the 3rd cycle chemotherapy and 
after doing a new assessment to measure 
response to chemotherapy.   
 
2.3.2 Radiotherapy  
 
The Gross Target Volume 70 (GTV 70) consists 
of gross lesion seen on CT, MRI or endoscopic 
findings and GTV LN is any LN more than 1 cm 
or LN with a necrotic center. Clinical target 
volume 70 (CTV 70) and PTV70 encompass 
GTV 70 and CTV 70 + 3 -5 mm margin or less 
near the organs at risk (OAR) like the brainstem. 
Clinical Tumor Volume 59.4 (CTV59.4)  include 
the whole  NP, anterior one-third of the clivus, 
base of the skull, inferior portion of sphenoid 
sinus, cavernous sinus, pterygoid fossa, Para 
pharyngeal space, posterior one-fourth of the 
nasal cavity/maxillary sinuses, inferior portion of  
soft palate, retropharyngeal LN, retrostyloid 
space, and bilateral cervical LN from  level IB to 
V. High-risk GTVP, GTVLN & CTV was given a 
radiotherapy dose of sixty Gray in thirty fractions 
divided into 2 phases. Phase 3 included ten to 
fourteen gray in five to seven sessions to GTVP 
and six to ten Gray in three to five fractions to 
GTVLN. Patients with N0 disease or lower neck 
(level IV and V) delivered a dose of 45-54 Gy at 
1.8 Gy per fraction. Table 1. Radiation therapy 
was given by 3D Conformal technique and was 
delivered by the high energy linear accelerator 
(Elekta, Precise Treatment System TM), Version 
5, with 6 MV and 15 MV photon energy. We tried 
multiple field arrangement field in field with 
segmentation technique was the best beam 
arrangement used achieving better coverage of 
the PTV without  exceeding the tolerance dose to 
the OAR. 
 
2.4 Follow-up 
 
Chemotherapy Toxicities either hematological or 
non-hematological were assessed after each 
cycle, while radiation toxicities were evaluated 
weekly for acute radiation toxicity and every 
three, six months for chronic ones. Adverse 
events were estimated according to the latest 
version of the National Cancer Institute's 
Common Terminology Criteria for Adverse 
Events version 4.0 (NCI CTCAE).After ending 
CCRT, patients were followed every three 
months during the first two years, every six 
months for the next two years, and then annually. 
 
2.5 Statistical Analysis 
 
Data were analyzed with SPSS version 22 and 
expressed as number and percentage. Kaplan–
Meier method used for analysis of the survival 
function. 
 
3. RESULTS 
 
3.1 Patient Characteristics 
 
Between August 2104 and August 2016, 36 
eligible patients diagnosed with nasopharyngeal 
carcinoma that referred to clinical oncology          
and nuclear medicine department, Mansoura 
University Hospitals incorporated in our study 
after the agreement of the ethical committee of 
Mansoura University. The median follow-up was 
23 months (Range 11-33). Males predominated; 
there were 25 (69%) men and 11 females (31%) 
with male to female ratio of about 2 to 1.The age 
ranged from 18 to 70 years with a median of 48 
years. Most patients had a PS  ECOG 1. There 
were 34 patients (95%) with ECOG 1 and only 2 
cases (5%) with ECOG 2. Co-morbidities 
encountered in only five patients, and the 
remaining 31 (86%) patients had no associated 
co-morbidities. Of the 36 patients, 12 (33%) were 
smokers. Symptoms at presentation were 
different according to T and N stage. Patients 
with N +ve disease mainly presented by cervical 
lymphadenopathy while, patients with N -ve 
disease came with nasal or ear symptoms. 
Patients with T3 and T4 came mostly with cranial 
neuropathy.  Almost all patients presented with 
more than one symptom. In general, the most 
common presenting symptoms were cervical 
lymphadenopathy (56%) followed by nasal 
symptoms (22%), cranial neuropathy (14%) and 
ear symptoms (9%)  Patients’ characteristics and 
staging detailed in Table 2. 
 
3.2 Treatment Outcome  
 
3.2.1 Response  
 
Thirty-four patients had ended the induction 
phase and all of them reassessed by MRI PNS & 
neck and endoscope with comparison with the 
baseline investigation. The response assessed 
according to the Response Evaluation Criteria in 
Solid Tumors (RECIST) [20]. The objective 
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response rate was 86% (CR 12%) for primary 
tumor and 100% (CR 62%) in the cervical LN 
after induction chemotherapy. Out of the 34 
patients that had started the CCRT, 33 patients 
had ended this phase and then reassessed by 
MRI PNS and neck, endoscopy and endoscopic 
biopsy if residual or suspicious residual, 45-60 
days after completing radiotherapy and the 
corresponding rate was 100% (CR) 91%.               
Tables 3 and 4. The three patients who had 
residual disease at the primary site after CRT; 
one of them was offered two cycles of adjuvant 
chemotherapy and became free, and the other 
two patients were followed up regularly and did 
not offered adjuvant treatment as they had SD 
after induction chemotherapy. One of those two 
patients had stable disease on follow-up, and the 
other one had PD after ten months and was 
offered 1st line chemotherapy two cycles then 
lost follow-up before assessment. 
 
Table 1. Suggested target volume and the prescribed doses for patients received CRT phase 
 
Target volume Description  Prescribed dose  
High risk GTV P  
 
Consists of all gross disease on physical 
examination and imaging  
60 GY/ 30 ttt followed by 10-14 
GY/5-7 ttt 
High risk CTV P  
 
Consists of GTV 70 + 3 mm margin or less           
(1 mm) around critical structures like the 
brainstem 
60 GY /30 ttt followed by 10-14 
GY/ 5-7 ttt 
High risk GTV LN Neck nodes: All nodes ≥ 1 cm or those with 
necrotic center 
60 GY /30 ttt followed by 6-10 
GY/ 3-5 ttt 
CTV 59.4 Include : The whole  NP , anterior one-third of 
the clivus ,base of the skull ,inferior portion of 
sphenoid sinus, cavernous sinus, pterygoid 
fossa ,Para pharyngeal space ,posterior one-
fourth of the nasal cavity/maxillary sinuses 
,inferior portion of soft palate, retropharyngeal 
LN ,retrostyloid space, bilateral cervical LN 
from  level IB to V. 
60 GY /30 ttt 
Lower neck  with LN-ve  Level IV & V LN 45-45 GY/25-28 ttt 
 
Table2. Characteristics of the study group patients (36 locally advanced NPC cases) 
 
Characteristic No. (36) % 
Sex Male 25 69 
Female 11 30 
Age     
Range(18-70) 
Median (48) 
18-40 14 39 
41-70 22 61 
ECOG 
P.S 
 0 23 64 
1 11 31 
 2 2 5 
Special habits 
 
No 29 81 
Smoking  6 16 
Co morbidities 
 
DM 2 6 
HTN 1 4 
Cardiac 2 6 
Pathology Undifferentiated carcinoma 36 100 
T stage  T1 13 37 
T2 11 31 
T3 10 27 
T4 2 5 
N stage  N0 10 28 
N1 6 17 
N2 19 53 
N3 1 2 
Symptoms  
 
Cervical lymphadenopathy 20 56 
Nasal symptoms 8 22 
Cranial neuropathy 5 14 
Ear symptoms 3 9 
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Table 3. Summary of the results of induction chemotherapy phase 
 
                              Response to induction CTH Patients finishing 
induction CTH 
Patients  
                   NP (34)                                         LN+(26) 
CR+PR PR CR CR+PR PR CR 
100% 10(38%) 16(62%) 86% 25 (74%) 4 (12%) 34 (94%) 36 (100%) 
 
Table 4. Summary of results of CCRT phase 
 
     Follow -Up failure         Response to CRT   Patients finishing CRT 
Distant Local 
0 0 (30) CR               (3) PR in NP NO (33)     
0 0 91% CR              9% PR % (100)  
CR (Complete response)-PR (Partial response)-SD (stationary disease)-NP (nasopharynx)-LN (lymph node ) 
 
3.2.2 Survival rate 
 
All of the 30 patients who achieved complete 
response remain disease free, no local 
recurrence, no bone or visceral metastases. 
Using the Kaplan-Meier method, the two-year 
DFS was 85% as shown in Fig. 1. The estimated 
two-year OS was 95% as shown in Fig. 2. 
 
3.3 Treatment Toxicity and Acute 
Adverse Events  
 
The TPF regimen was tolerable. Only two 
patients (6%) out of the 36 developed grade III 
febrile neutropenia and one of them (3%) 
developed grade III mucositis, diarrhea and 
grade III hepatic and renal impairment and did 
not complete the induction phase and excluded 
from the study. Thirty four patients had 
completed the planned three courses of TPF .No 
dose reduction needed during the induction 
phase. Chemotherapy toxicity recorded in the 
Table 5. Out of the 34 patients who entered the 
CRT phase, three patients (9%) had grade III 
mucositis, 2 of them had treatment interruption, 
but they completed the CRT phase and only one 
of them lost to follow-up and dropped out this 
phase. The median course of concurrent 
chemotherapy was 5 (1-8 courses). The number 
of patients who finished at least five courses               
of CT was 29 patients (85%). No significant 
hematological toxicities, vomiting or renal 
impairment encountered during the CRT phase. 
Skin toxicity of grade 1 was the commonest 
acute effects seen in 97% of cases Table 6.  
 
3.4 Late Toxicity 
 
After a median follow-up of 23 months, the 
patients showed a low incidence of severe late 
complication. Of the 33 patients who completed 
the concurrent CRT phase, no one developed    
G3 toxicity. The most common late radiation                 
effect was xerostomia with G 1 seen in 76%                  
of patients and G 2 in 24% of patients               
Table 7. 
  
Table 5. Hematological and non-hematological toxicities encountered in the study group 
during the induction phase 
 
Hematological G1 G2 G3 
N % N % N % 
Anemia 3 8 1 3 0 0 
leucopenia 6 17 2 6 1 3 
Neutropenia 4 11 2 6 2 6 
Neutropenic fever  0 0 0 0 2 6 
Thrombocytopenia 4 11 1 3 1 3 
Non hematological   20 55 14                39 2 6  
Nausea and Vomiting 
Diarrhea  28 77 2 6 1 3  
Hair loss 0 0 34 100 _ _ 
Mucositis 15 42 6 17 1 3 
Liver impairment 1 3 2 6 1 3 
Renal impairment 2 6 0 0 1 3 
Peripheral neuropathy 9 25 2 6 0 0 
 
 
Table 6. Acute radiation toxicities encountered in the study group during the CRT phase  
 
Grade 1       Toxicity        
6Anemia 
2 (Leucopenia 
2 (Neutropenia 
0 (Neutropenic fever 
2 (Thrombocytopenia 
4Nausea and vomiting 
1Liver impairment 
5 (Renal impairment 
5 (Mucositis 
33Skin toxicity 
 
Fig. 1. 2 
Fig. 2. 2 
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Grade 3       Grade 2        
0 (1 (3%)  (18%) 
0 (0)1 (3%) 6%) 
0 (0)1 (3%) 6%) 
0 (0)0 (0) 0) 
0 (0)0 (0) 6%) 
0 (0)2 (6%)  (11%) 
0 (0)1 (3%)  (3%) 
0 (0)2 (6%) 15%) 
3 (9%)26 (77%) 14%) 
0 (0)1 (3%)  (97%) 
 
 
- year DFS among all studied cases
 
 
-year OS among all studied pla
 
 
 
 
33794 
 
 
0) 
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Table 7. Late Radiation toxicities encountered in the study group who finished the CRT phase 
 
% G4 % G3 % G2   % G1 Toxicity 
0 0 0 0 24 8 76 25 Xerostomia 
0 0 0 0 0 0 6 2 Dysphagia 
0 0 0 0 0 0 9 2 Trismus 
0 0 0 0 0 0 6 2 Subcutaneous fibrosis 
0 0 0 0 0 0 3 1 Hearing deficit  
 
4. DISCUSSION 
 
Renewed interest in the role of neoadjuvant 
chemotherapy was made recently in managing 
locally advanced NPC. The NCCN panel 
recommends it as being category III after              
being category I while ESMO guidelines still 
recommend it as class I. Multiple trials were 
going aiming to define the best candidate and the 
best regimen for neoadjuvant chemotherapy in 
locally advanced NPC and to confirm whether 
NACT  affects the OS in comparison with CCRT 
[12-17].   
 
The main aim of our study was the evaluation              
of the efficacy and safety of neoadjuvant 
chemotherapeutic TPF regimen followed by 
CCRT for advanced non metastatic NPC. The 
primary endpoint was the response rate, and the 
secondary endpoints were to evaluate treatment 
toxicity, disease-free survival (DFS) and overall 
survival (OS) and if we can achieve better 
coverage to the PTV without exceeding the 
tolerance dose to the OAR with non-modulation 
RT techniques. 
 
Nasopharyngeal carcinoma is radio and chemo-
sensitive. Combined chemo-radiotherapy with or 
without adjuvant chemotherapy underwent 
extensive studies and proved to be the standard 
treatment line for advanced non metastatic NPC 
[3-6]. Various phase 3 and meta-analytic studies 
have confirmed that adjuvant chemotherapy 
gave no significant improvement in patients’ 
survival and was found to be poorly tolerated and 
has limited compliance because patients suffer 
substantial toxicities from CCRT and may be 
unfit to receive further chemotherapy [21-24]. 
Despite being the standard treatment, most of 
the results of CCRT are suboptimal as over 20% 
of patients still experience distant metastasis 
after CCRT, necessitating exploration of other 
intensive treatment modalities as neo-adjuvant 
chemotherapy for improving the patients survival 
rates [25].The reported studies clearly illustrate 
that, with neoadjuvant chemotherapy, tolerance 
and compliance are substantially better, and 
nearly 100% of patients can tolerate at least two 
cycles. However, induction chemotherapy using 
cisplatin or its combination, such as combined 
cisplatin, epirubicin and paclitaxel failed to 
improve the OS according to the results from 
several randomized clinical trials [26-28]. 
 
Docetaxel has demonstrated significant efficacy 
as a single agent or in combination with platinum 
in head and neck squamous cell carcinoma 
(HNSCC).Compared with paclitaxel, it has less 
neurotoxicity, which supports its combined use 
with cisplatin. Its efficacy in the treatment of 
HNSCC has been demonstrated in randomized 
clinical trials. The results from the TAX 3238 and 
TAX 3249 studies revealed that, when used with 
CCRT or RT, the addition of docetaxel to 
cisplatin and 5-FU (TPF) reduced the risk of 
death by nearly 30% [29-31]. Such encouraging 
results obtained by the TPF chemotherapeutic 
regimens in HNSCC were impressive for its use 
in locally advanced NPC. Further phase II and 
phase III trials have evaluated and confirmed the 
efficacy and tolerability of TPF regimen in locally 
advanced NPC and recently, recommend it as 
the optimal neoadjuvant regimen [12,15,32].    
 
In our study, Initial assessment after the 
induction phase showed that CR in the NP was 
achieved in 12% and 62% in the LN while PR in 
the NP was 74% and in the LN 38%. Stationary 
disease was seen in 17% mainly in the primary 
tumor with node -ve disease and no progressive 
disease was seen. Our results cope with the 
results of the meta-analytic study done by Du 
and his colleagues [25] that showed that 
neoadjuvant chemotherapy was a significant 
factor predicting good response rate for all 
patients with node-positive NPC (N2&N3)             
(P value 0.006). Also the high incidence of CR 
that occurred mainly in the LN after the induction 
phase in our study comes with the design of their 
prognostic model in which the LN status was one 
of the factors that should be taken into 
consideration in selection of patients who will 
benefit from NACT, however, other factors in the 
prognostic model should be also investigated. 
 
The opinion of  Kong and his colleagues [32] 
supporting the role of induction chemotherapy in 
locally advanced NPC through its ability to shrink 
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the GTV and so decreasing the dose to critical 
structures as brainstem and optic chiasma not 
achieved in the current study. Two of our cases 
were T4 No disease, one of them did not 
complete the induction phase and the other when 
assessed after the 3rd cycle revealed stationary 
course and on giving the CRT phase, the PTV 
was accepted to be covered by only 90% in order 
not to exceed the tolerance dose of the OAR. 
However, this is needed to be confirmed by 
much more cases. 
 
The most commonly recorded severe acute 
toxicity (≥ grade 3) in the most representative 
studies of NACT in NPC [10,33] were nausea/ 
vomiting (25.6%), followed by neutropenia 
(17.3%). In the current study, the incidence of 
grade 3 nausea and vomiting was only 6%, and 
this is probably due to more potent antiemetic 
used .Severe neutropenia was only seen in 6% 
of cases due to GCSF support. 
 
Regarding diarrhea and mucositis associated 
with induction chemotherapy, grade 3 seen in 
only one patient (3%), however, it was not 
observed in [10,33]. This difference between 
results may probably due to the use of 5-
fluorouracil in the TPF regimen while the 
regimens used in the previous 2 studies were 
taxanes and cisplatin only. 
 
Acute severe liver dysfunction and renal 
dysfunction were seen in only one patient (3%) 
while they were not experienced in [10,32,33] 
and this may be explained by the associated co-
morbidities in the patients included in our trial. It 
seemed that the regimen of TPF was tolerable by 
most of the patients as only two patients 
developed GIII toxicity and did not complete the 
protocol. These results cope mostly with the 
results of the studies utilizing TPF regimen in 
induction phase as in [12,15,32]. 
 
In the CRT phase, no significant hematological, 
gastrointestinal, renal toxicities or skin toxicities 
were noticed. For hematological toxicities, no 
grade III toxicities were seen in our study. Our 
results are better than the results of the two 
published studies on 2009 & 2012 [10,33] that 
showed  6.4%  grade 3 anemia and 26% grade 3 
leucopenia, 13% neutropenic fever and 1.1% 
grade 3 thrombocytopenia. As regard non-
hematological toxicity in the previous two studies, 
G3 nausea and vomiting was reported in 16.8% 
of cases, renal impairment in 6%, skin toxicity in 
8.4% and 28% had grade 3 mucositis. In our 
study no grade III non hematological toxicities 
were experienced except for 9% G3 mucositis 
and this is explained by the potent antiemetic 
measures used during CCRT, conformal RT 
techniques sparing the parotid gland and buccal 
mucosa in comparison with the conventional 
ones. 
 
Nasopharyngeal carcinoma is considered among 
the most difficult tumors to plan because of its 
complex anatomy, multiple targets with different 
dose prescriptions, a significant extension of                 
the treatment region and the number of 
structures at risk. Moreover, doses up to 70Gy 
with a conventional fractionation are prescribed. 
To overcome planning difficulties, highly 
sophisticated techniques such as intensity-
modulated radiation therapy (IMRT), intensity-
modulated arc therapy, or volumetric modulated 
arc therapy (VMAT) have been developed. 
These modern techniques gave much better 
results than does three-dimensional conformal 
radiotherapy (3DCRT), especially in the 
differentiation of dose distribution towards 
treatment targets and sparing of the OARs. 
However, these techniques cannot be universally 
used, due to unavailability of adequate 
equipment, organization or patient status, and 
this gives the 3DCRT the upper hand in the 
treatment of the most of the cancers including 
Head and Neck cancers. In our study, CRT 
phase was given utilizing 3D conformal 
technique due to unavailability of IMRT which 
was tailored to improve the PTV dose 
conformality and sparing of the OAR’s which 
were the biggest problems we faced. Various 
fields arrangement were tried but Field in field 
technique developed by Herassi and his 
colleagues [34], was the one which achieves our 
target. 
 
In the current study that was ended by 33 
patients, final assessment after CRT revealed 
that CR in the primary site and neck achieved in 
91% (30 patients) and PR in 9% (3 patients) in 
the primary tumor. The overall response rate is 
100% which is better than the results of Kong 
and his colleagues [32] that show an overall 
response of 94.9% with induction TPF followed 
by CCRT. The results of our study were 
comparable with the results of Bae and his 
colleagues [35] that reported an ORR of 98%. As 
regards the local control rate which reached 91% 
in our study, it was found comparable to the 
previous study. 
 
These encouraging results as regard the impact 
of NACT on loco-regional control were confirmed 
by these recently published phase III and meta-
analytic studies [12-17,25]. 
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In our study and after a median follow-up                   
period of 23 months, the incidence of local 
recurrence and distant metastases in patients 
who reach complete response (30 patients) was 
0%, and these are better results than those of 
Kong and his colleagues [32] that showed               
21 failures observed during follow-up. This 
difference in the incidence of loco-regional 
recurrence and distant metastases between our 
study and the previous one may be contributed 
to the larger number of patients and longer 
follow-up period in Kong et al than those of our 
study.  
 
Recently, the researchers have concluded that 
there is a significant improvement in the OS for 
locally advanced NPC patients who received 
induction chemotherapy in comparison with 
CCRT. [12-17] and the TPF regimen has been 
recommended to be the optimal neoadjuvant 
regimen [12,15]. The findings from our trial 
confirm these encouraging results where the 2-
year OS reached 95%, and the 2-year DFS 
reached 85%. However, our study lacks the 
comparative arm. 
 
5. CONCLUSION 
 
Neoadjuvant chemotherapy is an important line 
in treating advanced NPC as it has been 
confirmed to improve the OS compared with 
CCRT but the optimal candidate and the best 
regimen are needed to be defined. Extensive N 
stage (N2&N3) is one of the parameters to be put 
into consideration in the selection of the patient 
for NACT. The TPF regimen was well tolerated 
and had a manageable toxicity profile. The 
addition of TPF before CCRT significantly 
increased failure-free survival, OS and distant 
failure-free survival rates; however, long-term 
follow-up is required. The standard technique in 
advanced NPC is IMRT; however, if not 
available, 3D conformal techniques can be 
tailored to achieve the best coverage of the PTV 
without exceeding the tolerance dose to the 
OAR.   
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